Bris­tol My­ers, Foun­da­tion Med­i­cine ex­pand col­lab­o­ra­tion to ex-Turn­ing Point can­cer drug

Roche sub­sidiary Foun­da­tion Med­i­cine has ex­pand­ed a Big Phar­ma col­lab­o­ra­tion around its com­pan­ion di­ag­nos­tic and a po­ten­tial fu­ture block­buster.

The di­ag­nos­tics out­fit put out word Tues­day that it has reached a deal with phar­ma gi­ant Bris­tol My­ers Squibb. With no fi­nan­cials dis­closed, the col­lab­o­ra­tion would see Foun­da­tion Med­i­cine de­vel­op its biop­sy test, known as Foun­da­tionOne CDx, as a com­pan­ion di­ag­nos­tic for Bris­tol My­ers’ still-in­ves­ti­ga­tion­al oral ty­ro­sine ki­nase in­hibitor re­potrec­tinib.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER